OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomasPreclinical ...

Opko outlines Q2 2026 revenue of $127M-$132M as ModeX advances 5 clinical programs

ModeX pipeline progress, 4Kscore reimbursement catalysts, Q2 revenue guidance, cash/buybacks—read key takeaways.

ModeX starts dosing in MDX2003 trial for B-cell lymphoma

OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...
Pharmabiz

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...